Up 1.6% to $159.84, United Therapeutics (NASDAQ:UTHR), is one of today's notable movers. The S&P is currently trading fractionally lower to 2,097 and the Dow Jones Industrial Average is trading fractionally higher to 18,098.
United Therapeutics (NASDAQ:UTHR) is currently priced 4.5% above its average consensus analyst price target of $152.62. The stock should discover initial support at its 50-day moving average (MA) of $142.28 and subsequent support at its 200-day MA of $118.61.
Over the past year, United Therapeutics has traded in a range of $36.55 to $164.38 and is now at $159.84, 337% above that low. Over the last five market days, the 200-day moving average (MA) has gone up 0.7% while the 50-day MA has advanced 1.2%.
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.